U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE

CENTERS FOR DISEASE CONTROL AND PREVENTION

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

SURROGATE DATA WORKGROUP

+ + + + +

FRIDAY, MAY 8, 2009

+ + + + +

TELECONFERENCE

+ + + + +

The workgroup convened at 1:00 p.m., Dr. Jim Melius, Chair, presiding.

MEMBERS PRESENT:

JIM MELIUS, Chair JOSIE BEACH MARK GRIFFON WANDA I. MUNN PAUL ZIEMER

IDENTIFIED PARTICIPANTS PRESENT:

THEODORE M. KATZ, Acting Designated
Federal Official

NANCY ADAMS, Contractor to NIOSH

EMILY HOWELL, HHS

ARJUN MAKHIJANI, SC&A

JOHN MAURO, SC&A

ROBERT McGOLERICK, HHS

DAN McKEEL

JIM NETON, NIOSH ORAU

JOHN RAMSPOTT, General Steel Industries

BILL THURBER, SC&A

TOM TOMES, NIOSH ORAU

1 P-R-O-C-E-E-D-I-N-G-S 2 (1:04 p.m.)MR. KATZ: This is the Surrogate 3 Data Working Group. And this is Ted Katz. 4 I'm the acting designated federal official for 5 6 the Advisory Board. We'll start with roll call, beginning with the Chair of the Working 7 Group or all members of the Working Group. 8 CHAIRMAN MELIUS: Jim Melius. 9 10 MEMBER ZIEMER: Paul Ziemer. MEMBER MUNN: Wanda Munn. 11 Josie Beach. 12 MEMBER BEACH: No conflicts. 13 MEMBER GRIFFON: Mark Griffon. 14 15 MR. KATZ: Okay. And I know Dr. 16 Poston is out of the country and not joining Everyone else, since we're talking about 17 site today, if you could just address 18 19 conflict as well, as Mark did. Ziemer. 20 MEMBER ZIEMER: No conflicts. 21 No conflict.

Munn.

MEMBER MUNN:

1	CHAIRMAN MELIUS: Jim Melius. No
2	conflicts.
3	MEMBER GRIFFON: And Mark Griffon.
4	No conflicts.
5	MR. KATZ: Okay. On to NIOSH ORAU?
6	DR. NETON: This is Jim Neton. No
7	conflicts.
8	MR. TOMES: This is Tom Tomes. I
9	have no conflicts.
10	MR. KATZ: And SC&A team?
11	DR. MAURO: John Mauro. No
12	conflict.
13	MR. THURBER: Bill Thurber. No
14	conflicts.
15	MR. KATZ: Okay.
16	MEMBER ZIEMER: I thought I heard
17	Arjun on the phone before.
18	MR. KATZ: Yes.
19	DR. MAKHIJANI: Arjun. No
20	conflicts.
21	MR. KATZ: Okay. All right. And
22	then let's have other HHS or other federal
	i de la companya de

1	either employees or contractors.
2	MS. HOWELL: Emily Howell, HHS. No
3	conflicts.
4	MR. McGOLERICK: Robert McGolerick,
5	HHS. No conflict.
6	MS. ADAMS: Nancy Adams, NIOSH
7	contractor. No conflict.
8	MR. KATZ: Okay. Nobody from DOL
9	or DOE. And then members of the public who
10	want to self-identify?
11	DR. McKEEL: This is Dan McKeel. I
12	am the Texas City SEC petitioner. And I have
13	notified [Identifying Information Redacted],
14	who is the other petitioner, that this meeting
15	was being held.
16	MR. RAMSPOTT: John Ramspott in St.
17	Louis representing General Steel Industries.
18	MR. KATZ: Welcome, John.
19	MR. RAMSPOTT: Thank you.
20	MR. KATZ: Okay. Then are there
21	any staffers of congressional offices who
22	might want to self-identify?

(No response.)

MR. KATZ: Okay. I would just remind everyone on the line, I know you are familiar with this, but please, everyone who isn't speaking, mute your phone while you're not speaking. And use star 6 if you don't have a mute button.

MEMBER MUNN: John, I don't know if my phone is the only one that's doing this, but you sound quite muffled. I'm not hearing you. I hear you, but I don't hear you clearly.

MR. KATZ: Sorry. Okay. Jim, it's your agenda.

CHAIRMAN MELIUS: Okay. Yes. Today I wanted to focus on the Texas City Chemicals special exposure cohort. And that report had been referred to the Workgroup on Surrogate Data in order for review because much of the SEC evaluation report is based on surrogate data.

So we are doing the meeting today.

There were some difficulties with scheduling of the workgroup. And Wanda is on, but originally she didn't think she would be able to participate on this particular date for personal reasons.

So our only focus today is going to be on the Texas City. We are not going to talk directly about criteria for the use of surrogate data in a more general sense and so forth.

Actually, I have one sort of procedural question because my understanding was that Jim Lockey was the representative on this workgroup, not you, Dr. Ziemer.

MEMBER ZIEMER: I will go back and look at the list here. I believe that's correct. I was just listening in.

CHAIRMAN MELIUS: That's fine. I just wanted to note for the record that Jim Lockey is not in attendance. And, actually, I never heard back from him about whether he would be able to attend. I was actually at

NEAL R. GROSS

1	his university last week on another matter.
2	And he was out of town then. And he may not
3	be back yet.
4	MR. KATZ: Jim, you are correct on
5	both counts. And I think I did hear from
6	Lockey that he cannot attend.
7	CHAIRMAN MELIUS: Okay.
8	MR. KATZ: I probably said Poston,
9	but I meant Lockey.
10	CHAIRMAN MELIUS: Okay. You did
11	say Poston.
12	MR. KATZ: Sorry about the
13	confusion.
14	CHAIRMAN MELIUS: I was trying to
15	make sure that either the Web site was wrong,
16	my memory was wrong, or what.
17	MEMBER ZIEMER: Just for the
18	record, I am on our official list, which I
19	just opened up here. It's Melius, Beach,
20	Griffon, Lockey, and Munn are the members. So
21	that is correct.
	1

CHAIRMAN MELIUS: So, anyway, to

focus on the Texas City Chemical SEC report.

What I thought we would do is sort of briefly because these are in documents, at least the first two items.

One is just a brief summary from NIOSH about their evaluation report, a summary from SC&A about their review of that evaluation report, and then I would like to give Dan McKeel a chance to sort of speak about from a petitioner's perspective on are there other outstanding issues.

And what I really hope to do in this meeting is to try to identify issues that need to be dealt with and make sure that: one, there are no other issues that might have come up that haven't been identified yet or where we need more information before the Workgroup and the Board could take action on this SEC evaluation. So that's the intent. And I hope we can work through that relatively efficiently.

So starting with NIOSH? And, Jim,

NEAL R. GROSS

I don't know who is presenting.

DR. NETON: Yes. I am going to start off if that is okay. Tom Tomes is here for some more detailed technical support if we get into it beyond my current level of recollection.

Just to refresh everybody's memory, we issued the evaluation report in January of 2008 for Texas City Chemicals. And I believe that I presented our evaluation report to the Board at the Tampa meeting in April.

As Dr. Melius pointed out, our approach to reconstructing doses at Texas City relies solely on the use of surrogate data. We have no individual monitoring data at all from the site.

We relied on a number of reports in the literature. Notably there was an EPA, I believe, 1978 report that we relied heavily on. And to some degree, maybe the Florida Institute for Phosphate Research reports.

The surrogate model is

reconstructed or we believe plausibly reconstruction of demonstrates a bound for the uranium intakes that were there. As all remember, Texas City is similar to Blockson Chemical in the sense that they were making phosphate products and they were as a side issue pulling off uranium for the AEC.

So we developed models to assess the uranium intakes, all the other progeny associated with uranium in the uranium DK series as well including radon. So it was a fairly straightforward model. We put plausible upper bounds on the exposures for the covered time period.

Just briefly, SC&A had some findings. And I'm sure John Mauro will get into that in more detail. There were eight findings that were recognized by SC&A. They broadly fell into several categories.

And the most notable ones were the exposures we modeled were either too highly --

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

and, actually, three of the findings were in that category. One was too low. And the other findings tended to center around whether we needed to do more work to prove or to demonstrate that the plausible bounds were actually appropriate by looking at some other references that may have been available at the time.

NIOSH had prepared draft responses to these findings. The report, I believe, came out in July of 2008. But a number of developments occurred since the time we wrote the evaluation report or around the time we wrote the evaluation report that really will tend to change the focus of the report itself and probably address some of the findings of SC&A.

Those developments include the issuance of a surrogate data position by NIOSH in August of 2008, so a good seven months after we wrote the report. We have a position out there now.

NEAL R. GROSS

It was also almost at the same time that we were drafting the evaluation report, very shortly before the report was released, we received some new information from Department of Energy that helped define covered activities that were there and specifically the very time periods that needed to be addressed, which would tend to narrow the covered period substantially and more than likely reduce the amount of internal exposure to uranium, at least uranium, possibly other nuclides.

And then the third major issue that arose was the Advisory Board or the Working Group challenge at Blockson, the adequacy of the radon model. It indeed was the one and the same model we have applied to Texas City that we used for Blockson.

So that leaves open the issue as to how we go about reconstructing radon at Texas City because, as we know, the Blockson approach is still undergoing discussion. In

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1 fact, I am giving a presentation on that at 2 the upcoming Board meeting in Amarillo. So, in a nutshell, I think that 3 enough things have changed since we wrote the 4 individual evaluation report that we feel the 5 need to have an update of the report itself. 6 7 But, having said that, I'm not sure that we can at this point come up with an 8 approach to the radon because, like I say, it 9 10 is directly tied to how we do Blockson. that kind of remains a sticky issue with us 11 12 right now as to how we are going to move 13 forward with Texas City. And that's what I have in a nutshell. 14 15 CHAIRMAN MELIUS: Okay. Good. And 16 that was I think helpful clarification, that issue. 17 Anybody have any questions for Jim? 18 19 (No response.) I just have one 20 CHAIRMAN MELIUS: question to make sure I understand the report, 21 Basically you had no data at all on frankly. 22

1	Texas City to utilize production data or
2	otherwise?
3	DR. NETON: I'm sorry. We do know
4	what they did and the production quantities of
5	uranium and those types of things, your
6	typical source terms. I'm sorry. I didn't
7	CHAIRMAN MELIUS: Okay.
8	DR. NETON: We had no individual or
9	area monitoring information is what I should
10	have said.
11	CHAIRMAN MELIUS: Okay.
12	MEMBER MUNN: Just an extremely low
13	production number.
14	MEMBER ZIEMER: I have one other
15	question. You mentioned eight findings, Jim.
16	I'm just glancing back at the SC&A report. I
17	find that they have nine findings listed.
18	DR. NETON: Oh, there are nine?
19	I'm sorry. I made a mental error there. One
20	of the findings was related to the class
21	definition. I guess I kind of
22	MEMBER ZIEMER: Okay. The others

1	were the technical ones.
2	DR. NETON: The others were
3	technical.
4	MEMBER ZIEMER: Yes, yes. Okay.
5	Gotcha.
6	DR. NETON: The class definition
7	issue.
8	MEMBER ZIEMER: Thanks.
9	DR. NETON: We can certainly talk
10	about what I was trying to address, the
11	technical.
12	CHAIRMAN MELIUS: John, are you
13	presenting the
14	DR. MAURO: Yes. I will give you
15	the overview. And then, of course, we can go
16	into more detail. Bill Thurber is the author,
17	principal author, of this document.
18	But I think, Jim, you did a great
19	job in summarizing it. I would like to add a
20	couple of over-arching findings related to our
21	work. And that is we did heavily focus in
22	this particular review on the degree to which

the approaches taken to external/internal exposure, pre-operational/operational exposures, and the methods you used -- and we evaluated them against not the draft criteria that the Surrogate Data Workgroup developed.

We did have some significant findings in that area; that is, we felt that surrogate approach the for many scenarios the radionuclides exposure and really did fall short of selecting surrogate data that was indeed appropriately applied to the Texas City facility. So we have quite a bit of discussion on that matter in this report.

I think that is one of the issues, that certainly if you are revisiting some of these exposure models and assumptions, we do have certain suggestions in our report as to other sources of data that might be more appropriate in time and in operation, nature of the operations. So I wanted to add that.

There is the issue of plausibility.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

I think that is an important issue. You will notice that in the process of discussing the selection of the surrogate data, in some cases the surrogate data that was selected ended up with exposures that we found to be plausible and seemed to be appropriate, but in other cases we found the assumptions that were used and the surrogate data that were used really I think is a very important over-arching issue with regard to the question plausibility.

Certainly in many cases they were bounding to the point where they may have been bounding to the extent that one would consider it to be unrealistically high by one to two orders or magnitude.

We also found in other places where the doses, the surrogate data that was used resulted in underestimates. That is, we believe that the data set that was drawn upon as applied to this problem resulted in an underestimate for a particular radionuclide

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

scenario.

So that sort of couches the over-arching issues. Of course, we are prepared to go into the details, if necessary.

And if we do move down that road, I certainly would go to Bill Thurber to address some of the more specifics.

I think between the summary that Jim just gave and I just provided, that gives you a pretty good picture of where we are in this particular review.

CHAIRMAN MELIUS: Thanks. Any questions for John?

MEMBER MUNN: Yes. This is Wanda. I do have a couple of questions, John. Even though, admittedly, I didn't read and reread the body of your report as thoroughly as I would have liked to, it is not clear to me why you feel that the FIPR study in 1998 might be a better reference for this particular site than the EPA study that was done 20 years before.

It would seem that the earlier study might have more reverence, more relationship to the then defunct plant than one that was done 20 years later. I'm not clear in my mind about what the difference of the content of those two references was.

DR. MAURO: I will give you one reason why we were critical of the data. In many cases, at least two of the scenarios, there was only a single measurement.

MEMBER MUNN: Right.

DR. MAURO: And the Florida data, there was a much more comprehensive set of values upon which to draw. And we found that it's very difficult, you know, to take single measurements and say that we are being claimant-favorable.

There are other places where the measurements that were made were made for conditions. For example, I will use one example -- and, Bill, certainly please add to this -- where the measurements that were used

NEAL R. GROSS

1	were for operations that did not apply to
2	Texas City.
3	So there were two aspects of, I
4	believe, the Idaho work that we felt were
5	problematic. One was they were very limited.
6	I think in some cases it was just single
7	measurements. And in another case, the
8	measurements that were made were for
9	associative operations that really didn't
10	apply to Texas City.
11	Bill, do you want to add a little
12	bit to that?
13	CHAIRMAN MELIUS: This is the
14	Chairman. Bill?
15	DR. MAURO: Is Bill Thurber online?
16	I know we signed in.
17	MEMBER MUNN: Yes, he did.
18	MR. THURBER: I had the stupid mute
19	on. John, yes, that captures it very nicely.
20	DR. MAURO: Okay. Thank you.
21	DR. NETON: I don't know how
22	technical we want to get, but this is

generally I just want to maybe make a few points there, that I think the EPA data had more than just one pointer. We chose to report the ones that we used.

But since SC&A had made that comment, we have since gone back and evaluated our values against the FIPR data. In fact, they're somewhat comparable. They are not very different. And this is the kind of stuff we get into when we really sit down and go back and forth on the issues.

MR. THURBER: I don't disagree with that, Jim, but we felt that in applying the draft criteria on surrogate data that were available to us when we did this review, that one of the criteria spoke specifically to if you had to use surrogate data, to very strongly justify it.

And so we felt that it would have been more helpful if you had said, "Well, we looked at the FIPR data. And we looked at the Idaho data. And this is how we came to our

NEAL R. GROSS

position." And that seems to be a more robust approach and more consistent with how we were reading these draft guidelines.

DR. NETON: That is a good point.

We would certainly be prepared to flesh out,

therefore, in that level of detail.

with where we were too high, I think this new information that we have from the DOE will help immensely resolve that issue. I think that the main issue with being too high centered around NIOSH assigning or assuming that the work occurred over an entire work year when, in fact, it was limited to a very short period of time within a year.

We weren't convinced of that that we could prove that at the time. Now with the new DOE information, we will shorten that work period considerably and bring it more in line with what SC&A thought the values should be.

MEMBER MUNN: Which will bring us much closer to the question of plausibility.

NEAL R. GROSS

DR. NETON: Yes, I think so.

MEMBER MUNN: And plausibility is, without any question, a viable issue and one that needs to be addressed. I take some issue with SC&A's having lumped plausibility in with fairness.

And, speaking of fairness, we all know that fairness is the end "Gotcha" for all of us who would like to be politically correct and make sure that everyone in the world has a fair deal.

But where the truth is, fairness is almost impossible to evaluate even from one person to the next, much less across the kind of incidents that we are speaking of in these sites and in these specific activities.

Plausibility? Yes, with no question, a better job needs to be done in that regard. But I don't think you can lump that in with fairness and maintain that there is a serious fairness issue here.

CHAIRMAN MELIUS: Any other

1	questions or comments for John?
2	(No response.)
3	CHAIRMAN MELIUS: Okay. Can we
4	hear from Dan? Do you have any comments or
5	issues to raise?
6	DR. McKEEL: Yes. Hi, Dr. Melius
7	and members of the Board and NIOSH and SC&A
8	and everyone. First, I want to thank you for
9	allowing me to participate in this Workgroup.
10	I guess I have a comment first
11	about Dr. Neton's revelations today or at
12	least revelations to me. He mentioned
13	receiving new data from Department of Energy,
14	information that would shorten the work
15	period. This is the first time that I have
16	had any inkling of this.
17	DR. NETON: Dr. McKeel, I would
18	just like to comment quickly there. I believe
19	this was discussed in a March conference call,
20	with the petitioners, with Tom Tomes, where we
21	brought this up.

McKEEL: Well, I am the

DR.

1	petitioner. And I have repeatedly said to Dr.
2	Ziemer and Ted Katz, you know, this is the
3	real problem because the 3-11 transcript has
4	not yet appeared on OCAS. So I really don't
5	have access to that.
6	So, anyway, I certainly would say
7	that I want that information shared with me.
8	And I am presuming that that information, Dr.
9	Neton, was given to the Board. Is that
10	correct?
11	DR. NETON: The transmittal letter
12	was put on our Web site a long time ago, but
13	just recently we put the information on the O:
14	drive. So it's out there.
15	DR. McKEEL: The transmittal letter
16	from DOE was put on the OCAS Web site?
17	DR. NETON: Not the Web site. The
18	O: drive. Sorry. And then we
19	DR. McKEEL: So it really well,
20	I guess I am interested. When you say "the
21	transmittal letter" and you "put" something
22	"on the O: drive," do you inform SC&A or the

1 Board that new information is posted about a 2 site, Texas City or another one? I'm just talking about general procedures now. 3 In other words, how would they be 4 5 aware? DR. NETON: In general, we do. And 6 7 this is all part of the Working Group process. We will inform them as new information is 8 added. 9 10 I can't recall from a year ago or more now that if we actually notified them. 11 DR. McKEEL: 12 Okay. 13 DR. NETON: But it is our general practice to notify the Working Group of new 14 information that is posted. 15 16 DR. McKEEL: Okay. Second comment is that the general thrust of the over-arching 17 points that John Mauro mentioned were that 18 some of the surrogate data in the evaluation 19 report was not appropriately applied to Texas 20 And that seems to me to be a huge 21 City.

point.

The second huge point is that the evaluation report, which recommends denying the Texas City SEC, states that you all can accurately bound intakes and external doses. And now we learn that the radon model used does not bound it and, in fact, has to be re-thought through for Blockson and in the same way has to be thought through for Texas City.

So here is a point that is an old issue about timeliness, but it also applies to surrogate data. NIOSH admits that it has absolutely no real data about Texas City.

And in my recent letter to Congresswoman Sheila Jackson Lee trying to get her to help locate some documents, I mentioned that we have had tremendous difficulty getting real data from the Texas Health Department and the Texas Commission on Environmental Quality, TCEQ. So we are asking her to help us.

The point I want to bring out is this evaluation report was in January of 2008.

NEAL R. GROSS

And it's now May of 2009. You reconstruct the radon doses. There have been reconstructions done in that 17 dose no months.

So my point is -- and it sounds like the deliberations about this are going to go on for a very long time. So I would just like to state again that it seems to me not just the fair but the appropriate thing to do is to admit that this fight, the doses cannot be reconstructed based on SC&A's findings, Dr. Neton's admission that they have not got a valid radon model.

And my challenge also is that although the source term is somewhat defined, now we know that there is new information from DOE that changes the production period. So possibly that information changes the source term mask, for instance, that was processed.

I would also note that if you carefully look at what has been offered as definitions of source term, it is very

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

incomplete. We know the plant stopped. And then it was slow starting. And, you know, there is very scant information that defines the source term.

There are no pictures of the recovery building. There are no descriptions of the recovery building, no way to tell how that building was constructed with respect to air flow and air exchanges and so forth. I know those discussions well at Blockson.

So to me this is a situation where you have an AWE site with no monitoring data at all. And it deserved at the beginning, a long time ago, an 83.14. And now as this long period of time after the evaluation report was rendered, we still -- I mean, we're saying this morning we cannot correctly bound those doses in a way that satisfies SC&A. And the Board still has to make its deliberations.

Then the final point I want to make is that although we say we are going to concentrate just on TCC, I think it is heavily

NEAL R. GROSS

dependent on getting surrogate data criteria that, number one, are finalized by the Board and that are reconciled with the NIOSH set of OCAS IG-004 surrogate data criteria, which were put out months after the evaluation report was made.

So I just think it is extremely --I am going to try to stay away from the "fairness" word because I don't think that's a good word. But Ι don't think it's scientifically defensible. Why don't we put That's the word that seems to it that way? resonate. I don't think it's scientifically defensible to keep on going forward with an opinion that NIOSH recommended against the SEC being awarded in January of 2008 when new data that's come casts a large doubt on that.

And also I would say today that I would like Dr. Neton to tell us exactly what the new data is from Department of Energy and how this could decrease the work period. I don't understand that at all.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	So I guess that is what I want to
2	say for this portion of the talk.
3	CHAIRMAN MELIUS: Okay. Thanks,
4	Dan.
5	Jim, do you want to respond to the
6	last question or
7	DR. NETON: About the new
8	information?
9	CHAIRMAN MELIUS: Yes.
LO	DR. NETON: Yes. I think Tom Tomes
L1	is here. He could provide a brief summary of
L2	what we have and what changes it might
L3	produce. Tom?
L4	MR. TOMES: We received the new
L5	documentation in January of 2008. And I think
L6	at least three of those documents we hadn't
L7	seen before. And they were reported written
L8	by the AEC of activities that were ongoing in
L9	Texas City Chemicals during 1955 and '54, in
20	that time frame.
21	And it describes the problems with
22	the uranium recovery facility, how it never

really went into full operation because of problems with the fertilizer plant. There were design flaws with it. And there was a lawsuit, as a matter of fact, over the people who constructed it.

And so at the same time, they had a research contract with the AEC. That contract was for researching the leach zone phosphate material to try to find a way that they could economically recover the P-205 from that. And the assumption was that they could recover the P-205, that the uranium would come with it.

And that research centered basically on the phosphate. And they did analyze for uranium on a number of samples. There are some results in those records.

Basically, to summarize that, it just shows that the uranium recovery plant started up and failed and never started back up again. And there was some research going on at the same time.

When we wrote the evaluation

NEAL R. GROSS

1	report, we knew there was some development
2	work going on. We didn't know what it was.
3	And we didn't know the full story of the
4	recovery plant.
5	So the implausibly high doses that
6	had been mentioned were mainly a result of
7	assuming that there was some work going on
8	that could have been that high of a dose. And
9	that's what we did not address in the
10	evaluation report because when it was drafted,
11	we didn't have that information.
12	DR. NETON: So, Tom, the total
13	period of time the uranium was produced, do we
14	have a handle on that now, like what period?
15	MR. TOMES: The last quarter of
16	1953.
17	DR. NETON: So one quarter of
18	uranium production, which we believe produced
19	approximately, what, 300 pounds of uranium?
20	MR. TOMES: Yes.
21	DR. NETON: So that was the total
22	production in that last quarter, which this

new information allows us to speak pretty confidently about now.

DR. McKEEL: Well, my comment would be so we have gone from 12 tons for the well-defined source term in the evaluation report now to 300 pounds in one quarter.

So I would say that any reasonable person, scientist or not, would listen to this and say that the evaluation report of January 2008 is completely invalid and needs to be rewritten.

I would then say to me it simply is not reasonable, it is not consistent with the spirit of EEOICPA to continue to try to get better numbers to develop a new radon model that what you need to do is to say we don't know even the barest fact, which is a good solid definition of the source term. That is the minimum that you should need. And there are many things that are not known about this plant, in addition to that. And we have the findings from SC&A.

NEAL R. GROSS

So I would say that you have laid out an excellent case why the only appropriate thing to do under the Act is to award an 83.14 to that site.

And I want to just state again for the record, there have been two dose reconstructions done before the evaluation report was issued. The evaluation report comes out and says, "We can reconstruct dose."

So my question still remains, why didn't you do that? Why didn't you do a single dose reconstruction in those 17 months since January 2008?

And I hope the answer will be that NIOSH can not do what it says is to be done and that, honestly, before going into a months and months and months longer deliberation on Texas City, that the Workgroup would recommend to the Board to pass a sense of the Board that the evaluation report has been presented to the Board, it's been researched by SC&A, and the Board could make a vote in Amarillo that

NEAL R. GROSS

1 if the Workgroup would recommend it, 2 there should be an SEC awarded for Texas City. And I think that is the only appropriate 3 action. 4 So thank you again for letting me 5 6 say my thoughts. 7 CHAIRMAN MELIUS: Thanks, Dan. I have a question for John Mauro. 8 Were you or your staff aware of this new 9 10 information from DOE when you wrote your evaluation report? 11 We based it on --DR. MAURO: No. 12 the records that were available to us at the 13 time indicated that the 300 pounds 14 15 produced over a 3-month period. 16 So felt that assuming that exposures, the basic approach 17 used for external exposures, for example, was, 18 19 believe, the individuals were exposed for a three-year period. 20 And the amount of the uranium was 21

the amount that would fill

22

up a 55-gallon

drum, which is much more than would be associated with 300 pounds. So they basically used the Blockson approach to external dosimetry that we felt was inappropriate as a surrogate and also not plausible.

But no, we did not have this more recent information that Jim made reference to.

CHAIRMAN MELIUS: I am just trying to understand the critique you made in your evaluation report and sort of exactly what information it was --

DR. NETON: Dr. Melius, I think I might be able to clarify a little bit. We did believe all along that this 300 pounds was what was produced, but, as Tom mentioned, there were other developmental activities that were under contract with AEC during that whole year.

And we had no knowledge at the time we wrote the evaluation report as to what those development activities were. We assume they could have been related to the uranium

NEAL R. GROSS

1	production or something of that nature.
2	And so then we assume an entire
3	year's worth of production of uranium just to
4	be conservative.
5	CHAIRMAN MELIUS: I thought I
6	understood that. And then I was a little
7	confused when I looked at the SC&A report and
8	some of their
9	DR. NETON: This new information
10	essentially just clarified in our mind that it
11	would be totally appropriate to do what SC&A
12	suggested, and it is to bound the exposures
13	using 300 pounds in that one quarter, which is
14	what we are prepared to do.
15	CHAIRMAN MELIUS: Anybody else on
16	the Board have any questions about this issue?
17	MEMBER MUNN: No. It seems fairly
18	obvious we have to wait for the additions to
19	the evaluation, which incorporate the more
20	firm information that we now have.
21	CHAIRMAN MELIUS: Correct. And any
22	other comments on that?

(No response.)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

CHAIRMAN MELIUS: I have, I guess, a question for Jim Neton. What would your time frame be on that for issuing a revised report?

Well, I don't think a DR. NETON: revised report would take too terribly long because it's a fairly simple source term. have a concern, though, about getting out a report that would address the radon the current ongoing discussions because of about Blockson and the appropriateness of that It would be not the exact Blockson approach. approach calculations but similar а very probabilistic model that we would use.

So we could reissue the report, but I would like to have some final resolution on the radon issue with the Advisory Board, rather than just go ahead and incorporate our current version into the evaluation report.

MEMBER MUNN: Jim's not alone in wishing to see that.

NEAL R. GROSS

CHAIRMAN MELIUS: I am sure.

DR. NETON: Maybe to move things forward, we could issue the report. If the radon is not resolved at the Amarillo meeting, we could issue it just to move discussions forward on all the pieces except the radon.

Of my questions back to the radon, I sort of hesitate to raise it, but my understanding was that I asked a more generic question about, I think, either at the Board meeting or one of the Workgroup meetings on Blockson. Was your policy going forward to apply the what's called, the so-called Blockson model at all other, you know, the similar sites involving radon exposure?

At that time I believe the answer was you weren't sure. You might would take the approach that is most suited to that particular site now. I may not be quoting --

DR. NETON: I remember the question. I think I said something to the

NEAL R. GROSS

1 effect that we would reserve the right to use 2 that where we felt it was appropriate --CHAIRMAN MELIUS: Yes. That sounds 3 4 Florida 5 DR. NETON: the Institute of Phosphate data Phosphate 6 7 Institute -- Florida Institute of Phosphate But in looking at the Texas Research data. 8 plant, it is more of a Southern plant. 9 So 10 that criteria is sort of fulfilled, but the data tend to be more contemporaneous. 11 These are back in the same era as 12 13 Blockson. So you run into the same issues with building ventilation rates and such, but 14 we feel we know enough about the source term 15 and the building footprint and such or the 16 size of the building that we could, you know, 17 the same analytical approach that 18 use 19 developed for, well, that SC&A developed that we are adopting for the radon, bounding radon 20 concentrations. 21

NEAL R. GROSS

MELIUS:

CHAIRMAN

22

Now,

Okay.

1	that's a
2	MEMBER BEACH: And, Dr. Melius,
3	this is Josie. I have a question.
4	CHAIRMAN MELIUS: Sure.
5	MEMBER BEACH: Page 7 of SC&A's
6	report reminds us that we had only assigned
7	them to do a focus review and only step one of
8	a two-step process was actually completed.
9	Do we need to assign them to look
LO	into that further?
11	CHAIRMAN MELIUS: Thanks for
L2	bringing that up. I would think that SC&A
L3	probably should not do anything more until
L4	NIOSH issues a revised report unless I am
L5	missing something that would be sort of worth
L6	doing.
L7	MEMBER BEACH: Okay.
L8	CHAIRMAN MELIUS: Short of that
L9	MEMBER MUNN: It would put us in
20	the position of having to have SC&A then look
21	at yet another document after NIOSH has
	1

revised the one that we used as the basis for

our discussion so far.

CHAIRMAN MELIUS: Correct. I mean,

I think we could make a decision on that when

we see the revised report. It's a fair

statement not to prejudge that and as to

whether it would be necessary or not, but I

guess I wouldn't necessarily see any need for

any work between now and the time that that

revised evaluation report is published by

NIOSH.

I don't know of anybody else from the Workgroup or Board has a difference on that or a comment.

MEMBER MUNN: No, it seems logical that until you get some of the uncertainty that has existed in the original report at least addressed by the forthcoming corrections and additions, that we have no basis for reevaluation.

CHAIRMAN MELIUS: Correct. I guess the only possibility -- and I'm not sure this is necessary, but were there a technical issue

NEAL R. GROSS

that SC&A raised in their evaluation report that NIOSH didn't understand or had questions And it might be facilitated by having about. sort of a technical call or consultation. Ι think that kind of activity might be appropriate, rather than have to revisit the issue a second time with a revised report. But other than that, I can't see

But other than that, I can't see any need for anything else. John Mauro, do you have any comments on that?

DR. MAURO: Yes. I fully agree that to initiate step two at this time would be premature.

CHAIRMAN MELIUS: Yes.

DR. MAURO: And I think after the revised work comes out, at that time what the Workgroup would like us to do will be dictated I guess by the extent and complexity of changes. It may be something that when you read, it's very straightforward.

And maybe some technical call will suffice after the report is issued or it may

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1 turn out that the Workgroup may decide that 2 no, they would like us to do some more. It's hard to say right now. 3 had, 4 MEMBER MUNN: Ι I hoped, correctly assumed that any technical exchange 5 6 that felt was needed by either party would, in 7 fact, take place without actual further urging from the Workgroup. Am I correct in that, 8 John, Jim? 9 10 DR. MAURO: Usually we get approval by the Workgroup for a technical call if one 11 is deemed needed. So what I am hearing is 12 13 SC&A asserted we would be more than happy to talk to Tom Tomes and Jim about our findings 14 if there's any question about any of it. 15 And as long as that is okay with 16 the Workgroup, we will certainly do that if 17 need be. 18 19 CHAIRMAN MELIUS: Yes. I mean, I don't see any problem with that. I would just 20

NEAL R. GROSS

Workgroup or at least the Workgroup Chair.

I think request that you would notify the

21

1	MEMBER ZIEMER: Yes. This is
2	Ziemer. I think the practice is raised on the
3	side of the Workgroup members because
4	Workgroup members have the option of listening
5	in on those technical discussions anyway.
6	MEMBER MUNN: I will try to listen
7	in and keep quiet.
8	DR. MAURO: Fine. Absolutely, Jim,
9	if there is anything, Tom, if there is
10	anything, you would like to discuss regarding
11	our findings, any of the more detailed stuff,
12	let us know. And we certainly will inform the
13	Workgroup when that is scheduled.
14	DR. NETON: Yes. We would be happy
15	to do that. Right now I can't think of
16	anything that, you know, we need to discuss,
17	but it may come up once we start doing our
18	revision.
19	CHAIRMAN MELIUS: Good. I have one
20	question. I think this is for Ted Katz. Dan
21	McKeel mentioned the I guess it's the

transcription related to a March 2008 call

with the petitioners that has never appeared on the Web site.

MR. KATZ: Yes.

DR. NETON: Dr. Melius, I think

that was a NIOSH and a petitioner call, which those aren't transcribed. Those are typically just -- I don't know, Tom. They're just meetings to discuss the evaluation report itself with the petitioners to answer any questions they might have. That's when this discussion about the new data came up.

CHAIRMAN MELIUS: Okay. Well, I am just responding to what I think I heard you --

DR. McKEEL: I was talking about the March 11th, 2009 Surrogate Data Workgroup.

And that's what I thought Jim was referring to. I mean, I am not sure about the March technical call.

CHAIRMAN MELIUS: I think Jim, Jim
Neton, -- too many Jims here -- Jim Neton was
I guess referring to a call with the
petitioners.

NEAL R. GROSS

DR. McKEEL: Well, I am the only
petitioner besides [Identifying Information
Redacted]. There are two of us.
CHAIRMAN MELIUS: Okay.
DR. NETON: And Tom Tomes is
sitting here. He recalls discussing this with
you during that conference call.
DR. McKEEL: And what was the date
of that conference call? Maybe I can look
that up?
MR. TOMES: March 13th, 2008.
That's what I recall.
DR. McKEEL: Oh, March 13th, 2008?
MR. TOMES: Yes, correct.
DR. McKEEL: Well, okay. So I
guess since your question is to Ted Katz,
then, you know, I will just mention I assume
to get that report from DOE, I will have to
file a FOIA request. Is that correct under
the current that it's not available to me
through FACA section 3(b), that because it was

not given to the Board directly, I have to do

1 a FOIA? Is that correct? 2 MR. KATZ: Yes. Dan? DR. McKEEL: Yes? 3 This is Ted. 4 MR. KATZ: These interactions that OCAS has with petitioners, 5 6 yes, you have to FOIA for that. That's 7 correct. But the question I McKEEL: 8 don't understand is, will there even be a --9 10 there won't be a transcript of that meeting. So all I request is some DOE documents that I 11 don't even know the name of that was discussed 12 13 at some meeting on March the 13th, 2008 for which there are no minutes, 14 summary, 15 transcript. 16 Ι what I would ask, quess Neton, it seems to me that things have gotten 17 far out of kilter when NIOSH can't even write 18 19 me an e-mail and tell me the name of the document because that would greatly facilitate 20

making a FOIA request for a specific document,

rather than some vague request that the FOIA

21

1	office would have no idea what I was talking
2	about and I don't have any idea what I am
3	talking about.
4	MR. KATZ: Dan?
5	DR. McKEEL: Yes?
6	MR. KATZ: I'm sorry. This is Ted.
7	I don't know of any reason why you can't be
8	given the name of a document to FOIA.
9	DR. McKEEL: Well, you may say
10	that, but I can tell you that I have written
11	Larry Elliott about Texas City. The first
12	time I ever wrote him I asked him this was
13	before the evaluation report. I asked him,
14	could he please inform me what information
15	NIOSH had or OCAS had about Texas City
16	Chemicals.
17	And he and Laurie Breyer assured me
18	that they had three documents for Texas City.
19	And after much urging, they sent me the SRDB
20	database listing, which gives the SRDB number.
21	And then I wrote back and said, you
	1

know, "This is not helpful because I don't

know what those numbers mean. Can't you at least give me like a basic bibliographic citation, the name, the title, the year, the report number, pages?"

And he refused. They refused. They said they would not do that. So you may not know a reason why I shouldn't get it, but all I can tell you is that, practically speaking, NIOSH has refused to divulge that kind of information.

And I also don't see any reason why they couldn't and shouldn't do that.

MR. KATZ: Jim or Tom, do you have the date of the memo from DOE or whatever the documentation was that was sent over that you can -- if you have it available, of course, you can just state it for the transcript and he can --

DR. NETON: Yes, Ted. It is a Department of Energy letter dated January 7th, 2008 from Dr. Pat Worthington to Larry Elliott.

NEAL R. GROSS

	MR. KAIZ: And the subject? Can
2	you just give the subject or whatever it has
3	as the subject line or whatever it might have
4	accordingly as identifier?
5	DR. NETON: It's a response to our
6	request for further research into Texas City.
7	MR. KATZ: Okay. I think that is
8	very exact identifying information.
9	MEMBER ZIEMER: This is Ziemer.
10	Did you say earlier, Jim, that that material
11	was on the O: drive?
12	DR. NETON: Yes, it is.
13	MEMBER ZIEMER: Okay. Thank you.
14	MR. TOMES: Just recently added.
15	And I haven't notified any of the Workgroup
16	that we put it on there yet.
17	MEMBER ZIEMER: I was looking in
18	the OCAS updates. And I didn't see any
19	reference to it or any notices that it was put
20	on.
21	DR. NETON: Yes. We need to get
22	the e-mail to the Working Group and SC&A as

well. It's in the Texas City folder. 1 2 MEMBER ZIEMER: I know on some of the workgroups, the -- your liaison person, 3 like Mark Rolfes or one of the others for the 4 various workgroups will tell the workgroup 5 6 when they are putting various documents on the O: drive. 7 DR. NETON: Right. 8 MEMBER ZIEMER: I don't think it's 9 10 a formal procedure, but it's certainly done as a matter of general practice if there is a 11 liaison person. 12 So I think in this case it would be 13 appropriate if, Tom, you would do that as a 14 15 regular thing for this particular case, it 16 would be helpful. MR. TOMES: We certainly will. 17 The letters have been on there for some 18 19 Just the documents themselves were just recently added. And I will send an e-mail 20 21 out.

NEAL R. GROSS

ZIEMER:

MEMBER

22

again,

And,

1	although the petitioners don't have access to
2	the O: drive, I don't see any reason why they
3	shouldn't be made aware that something has
4	been placed there. Is that a problem so they
5	know of its existence?
6	DR. NETON: I don't see that that
7	would be a problem, no.
8	DR. McKEEL: I would certainly
9	appreciate that. And, again, I would say
10	about this particular set, even though the
11	comment was that there was a letter from Pat
12	Worthington to Larry Elliott January 7th,
13	2008, there's also mention that there were
14	documents
15	DR. NETON: Right. That's
16	DR. McKEEL: accompanying the
17	letter. And that's really what I want, of
18	course, is the letter and the document.
19	DR. NETON: I understand. The
20	letter had attached to it these documents.
21	DR. McKEEL: Well, I don't know
22	whether the letter referred specifically to

1	the names of the documents. If it's in the
2	body of it, that would be fine. Eventually I
3	would have to send a FOIA for the documents
4	and the letter.
5	DR. NETON: I think if you could
6	just send and say we want the documents that
7	were listed in that letter would be sufficient
8	in my mind.
9	DR. McKEEL: Okay. Sure. That
10	would be fine. All right.
11	CHAIRMAN MELIUS: Any other
12	comments or questions?
13	MR. KATZ: I would just like to
14	clarify because there was also the question
15	about a Surrogate Data meeting. I thought it
16	was set on March 11th, but I don't see a
17	record of a March 11th Surrogate Data meeting,
18	not to say that that's not correct but
19	CHAIRMAN MELIUS: I don't believe
20	there was one.
21	MR. KATZ: Okay. Okay. Thanks.
22	All right.

1	DR. McKEEL: Maybe it was another
2	meeting. Maybe it was the other workgroup on
3	
4	CHAIRMAN MELIUS: The workgroups
5	MR. KATZ: I don't see a March 11th
6	meeting at all of the Board, of any workgroup
7	of the Board. But, again, something could be
8	wrong with the Web site listing.
9	DR. McKEEL: No. I'm probably
LO	incorrect.
11	DR. MAURO: Ted, this is John
L2	Mauro. I'm just looking at my calendar.
L3	DR. McKEEL: Yes.
L4	DR. MAURO: And I noticed that I
15	marked on my calendar for March 11th there was
L6	a TBD 6000 Workgroup meeting.
L7	DR. McKEEL: Yes.
L8	MR. KATZ: You are talking about
L9	2009. Sorry. I'm looking at 2008.
20	DR. MAURO: Oh, I am talking about
21	2009. Yes. I'm sorry.
22	MEMBER ZIEMER: You want to go back

1	a year.
2	DR. MAURO: I'm sorry.
3	DR. McKEEL: No. I am talking
4	about there was a 3-11-09 I guess it was a TBD
5	6000 Workgroup.
6	DR. MAURO: Yes. There was. I
7	have that in my calendar.
8	DR. McKEEL: Oh, okay. Thank you.
9	MR. KATZ: Okay. If it's not up
LO	there yet, that may be just getting a Privacy
11	Act review.
12	CHAIRMAN MELIUS: I'm sorry, but
13	that is not relevant to today. So that's
L4	okay.
L5	DR. McKEEL: Okay. Thanks.
L6	CHAIRMAN MELIUS: Anything else
L7	before we confuse ourselves all further? We
18	can barely tell what year we are all in,
19	right?
20	(No response.)
21	CHAIRMAN MELIUS: If not, then
22	thank everybody for participating. And some

1	of you I will see in Amarillo next week.
2	(Whereupon, the foregoing matter
3	was concluded at 2:05 p.m.)
4	
5	
6	
7	
8	
9	
10	
11	

NEAL R. GROSS